US20010003590A1 - Process for manufacturing tablets for the sustained release of active principle(s) - Google Patents
Process for manufacturing tablets for the sustained release of active principle(s) Download PDFInfo
- Publication number
- US20010003590A1 US20010003590A1 US09/733,668 US73366800A US2001003590A1 US 20010003590 A1 US20010003590 A1 US 20010003590A1 US 73366800 A US73366800 A US 73366800A US 2001003590 A1 US2001003590 A1 US 2001003590A1
- Authority
- US
- United States
- Prior art keywords
- emulsion
- active principle
- tablets
- spraying
- powder mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000013268 sustained release Methods 0.000 title claims abstract description 17
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title claims description 31
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000000839 emulsion Substances 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 15
- 239000012530 fluid Substances 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims description 17
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical group OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- -1 fatty acid esters Chemical class 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 239000002563 ionic surfactant Substances 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 238000005507 spraying Methods 0.000 abstract description 21
- 239000007764 o/w emulsion Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 38
- 239000008187 granular material Substances 0.000 description 20
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 18
- 239000002245 particle Substances 0.000 description 13
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 12
- 229960001259 diclofenac Drugs 0.000 description 12
- 229960000278 theophylline Drugs 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 239000002960 lipid emulsion Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Definitions
- the invention relates to a process for manufacturing tablets for the sustained release of active principle(s), as well as to the tablets thus obtained.
- tablette for the sustained release of an active principle denotes a tablet which can extend the therapeutic effect of the active principle in tissues or in the blood over a sustained period of time (see in particular “The Science and Practice of Pharmacy”, 19th edition, Remington 1975).
- documents, FR-A-2 417 982 and HU-A-9960 disclose a process for manufacturing delayed-action tablets by wet granulation. More specifically, the powder mixture comprising the active principle and the various adjuvants is blended with a granulation liquid consisting of an aqueous emulsion based on a hydrophobic component such as stearic acid and nonionic hydrophilic components such as polysorbates. The resulting wet mass is then dried, after which it is passed through a screen and the granules obtained are then pelletized so as to obtain tablets. The steps of blending, screening, drying and pelletizing the powder mixture make this process long and expensive.
- document WO 87/04070 discloses a process for spraying onto tablets an aqueous dispersion prepared by redissolving a dried lipid emulsion, based on wax or on hydrogenated oils, in water.
- Document JP-A-53 062 821 discloses a process consisting in emulsifying a lipophilic substance melted in an aqueous phase and then in coating a pharmaceutical preparation by spraying with this emulsion at elevated temperature, above the melting point of the lipophilic substance (technique known as dry-spraying). Besides the fact that nothing is indicated regarding the nature of the coated pharmaceutical preparation, this technique has the drawback of resulting in, during spraying, an evaporation of the aqueous phase and thus in a modification of the coating conditions.
- Document WO 98/14176 discloses a process for manufacturing tablets for the sustained release of active principle which are obtained by tableting granules that are hot-coated with a lipid matrix agent. This hot-coating technique not only has the drawback of giving rise to an additional energy expenditure, but also of requiring an adaptation of the standard equipment.
- the invention proposes a process for manufacturing tablets for the sustained release of active principle(s), in which:
- the emulsion obtained is sprayed onto a powder mixture comprising at least the active principle
- the powder thus treated is subjected to a tableting step, in order to obtain tablets.
- the powder mixture comprises not only the active principle but also the formulation excipients.
- formulation excipient denotes the excipients required to formulate the desired presentation form.
- the tableting step can be carried out using any known excipient intended to promote the said tableting.
- the spraying-air temperature is between 20° C. and 60° C., advantageously 25° C., the temperature of the emulsion being set at between 20° C. and 25° C.
- the initial powder mixture is subjected beforehand to a granulation step in order to obtain granules.
- the said emulsion is advantageously prepared by phase inversion, so as to modify the particle size distribution, thus making it possible to reduce the particle size and hence the viscosity of the emulsion.
- the oil-in-water fluid emulsion comprises from 5% to 35% by weight of fatty substance.
- the said particles are coated in a proportion of from 3% to 100% by weight with fluid emulsion, advantageously from 10% to 60%.
- the fatty substances are chosen from the group comprising fatty acids, hydrogenated oils, fatty acid esters of glycerol or of polyols, and natural waxes.
- the fatty substance chosen is glyceryl behenate sold by the Applicant under the trade name Compritol® 888 Ato.
- the fatty substance is glyceryl palmitostearate sold by the Applicant under the trade name Precirol® Ato 5.
- the emulsion also contains an emulsifier or surfactant.
- the surfactant used is chosen from nonionic and/or ionic surfactants.
- the emulsifier will be chosen so as to make the emulsion fluid and stable and to ensure the absence of formation of a foam.
- the emulsifier must be pharmaceutically acceptable.
- the emulsifier advantageously chosen is polyethylene glycol 4000 palmitostearate.
- the emulsifier is sodium lauryl sulfate used in a proportion of from 0.5% to 1% relative to the weight of the emulsion. Beyond 1%, no improvement of the emulsion is obtained and the formation of a foam is observed.
- the viscosity of the oil-in-water fluid emulsion is set at between 10 and 70 centipoises.
- the invention also relates to the tablet for the sustained release of active principle(s) which can be obtained by the process described hereinabove.
- FIG. 1 is a representation of the release profile of a tablet having zero-order kinetics for dissolution of the active principle.
- FIG. 2 is a representation of the release profile of a tablet having first-order kinetics for dissolution of the active principle.
- FIG. 3 represents the release profile of theophylline granules at a spraying-air temperature of 25° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 4 represents the release profile of theophylline granules at a spraying-air temperature of 60° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 5 represents the release profile of theophylline granules at a spraying-air temperature of 25° C. for the spraying of an emulsion based on Precirol® Ato 5.
- FIG. 6 represents the release profile of theophylline granules at a spraying-air temperature of 60° C. for the spraying of an emulsion based on Precirol® Ato 5.
- FIG. 7 represents the release profile of theophylline tablets at a spraying-air temperature of 25° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 8 represents the release profile of theophylline tablets at a spraying-air temperature of 60° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 9 represents the release profile of Diclofenac tablets manufactured from an emulsion based on Compritol® 888 Ato or Precirol® Ato 5 at a spraying temperature of 25° C.
- FIG. 10 represents the release profile of the same batch of Diclofenac tablets manufactured from an emulsion based on Compritol® 888 Ato or Precirol® Ato 5 before and after stability at 40° C.
- FIG. 11 represents the release profile of Diclofenac tablets manufactured from an emulsion based on Precirol® Ato 5 at a spraying-air temperature of 25° C.
- zero-order dissolution kinetics denotes the constant and uniform release of the active principle as a function of time. This release may be represented graphically in the form of a curve expressed by the following equation:
- first-order kinetics correspond to a release proportional to the amount remaining in the presentation form envisaged and which decreases exponentially with time (see FIG. 2).
- Example 1 the in-vitro release kinetics of the active principles are determined in a dissolumeter (conventional Sotax) in accordance with the European and US pharmacopeas, at pH 1.2.
- the spin speed of the paddles is 100 rpm.
- Granules corresponding to the formula below are prepared: theophylline monohydrate: 30 grams lactose: 41 grams wheat starch: 16 grams sodium carboxymethylcellulose: 1 gram microcrystalline cellulose: 12 grams
- the granules are manufactured by wet granulation in a rotating-paddle Guedu mixer-granulator, carrying out the following steps:
- a lipid emulsion comprising:
- Compritol® 888 or Precirol® Ato 5 is used as fatty substance.
- the fatty substance and the surfactant are heated until they have completely melted.
- the distilled water, heated to the same temperature, is added slowly with stirring.
- the addition of water gradually converts the initial water-in-oil emulsion into an oil-in-water emulsion.
- the emulsion is then homogenized with a Polytron homogenizer for three minutes in order to reduce and homogenize the size of the oil droplets.
- a machine with a flow of fluidized air is used, the fluidization-air temperature of which is set at 25° C. or 60° C.
- the fluidization pressure is set at about 1.5 bar.
- the spraying rate is adjusted to 10 grams per minute.
- FIGS. 3 and 4 represent the release profile for theophylline granules coated with a lipid emulsion based on Compritol® 888 for spraying-air temperatures of 25° C. (FIG. 3) or 60° C. (FIG. 4).
- the proportion of Compritol® 888 ranges between 10% and 30% relative to the mass of solids used.
- FIGS. 5 and 6 represent immediate-release profiles when the emulsion used is based on Precirol® Ato 5.
- the granules coated with Compritol® are then subjected to a step of tableting using a Frogerais OA alternating tableting machine having punches of reference size D10-R10.
- a mixture of talc and magnesium stearate, each representing 1% by weight relative to the total weight of the granules, is used as tableting excipient.
- the tablets obtained have an average weight of 402 mg and an average hardness of 5.7 kg.
- FIGS. 7 and 8 show, the tablets obtained from the granules manufactured at a spraying temperature of 25° C. (FIG. 7) or of 60° C. (FIG. 8) show zero-order kinetics for a Compritol® concentration in the emulsion of 30%.
- the process of the invention has the advantage of being able to be carried out at a spraying-air temperature of about only 25° C., which not only facilitates the various operations but also reduces the manufacturing cost, in particular in terms of energy consumed.
- Diclofenac particles are prepared under the same conditions as those of Example 1, starting with a Diclofenac/dicalcium phosphate mixture in proportions of 50/50.
- the granules are then coated with an emulsion under the same conditions as those of Example 1, at a spraying-air temperature of 25° C., while varying the nature and concentration of the lipid substance used.
- FIG. 10 represents the release profiles of Diclofenac tablets coated with lipid emulsions comprising 20% of Compritol® 888 Ato or 20% of Precirol® Ato 5, before and after twelve months of stability at 40° C. and 75% relative humidity (accelerated stability).
- a fluid emulsion is prepared containing 10% of identical fatty substance under the same conditions as those used in Examples 1 and 2.
- the powder mixture consisting of a mixture of Diclofenac/dicalcium phosphate in proportions of 50/50 is then coated so as to obtain coated particles with good tableting properties.
- the emulsion is sprayed onto the particles under the same conditions as those of Example 1, at a spraying-air temperature of about 25° C.
- the step of tableting the coated particles is carried out on an industrial rotary tableting machine.
- the tableting characteristics and the characteristics of the tablets obtained are as follows: Coated particle 92% Encompress 6% Talc 1% Magnesium stearate 1% Average weight of the tablet 280 mg Hardness 33 Newtons
- FIG. 11 represents the release profile of Diclofenac tablets in which the proportion of Precirol® Ato 5 relative to the mass of solids used is 20%.
Abstract
Description
- The invention relates to a process for manufacturing tablets for the sustained release of active principle(s), as well as to the tablets thus obtained.
- In the description and in the claims, the expression “tablet for the sustained release of an active principle” denotes a tablet which can extend the therapeutic effect of the active principle in tissues or in the blood over a sustained period of time (see in particular “The Science and Practice of Pharmacy”, 19th edition, Remington 1975).
- Several processes have been proposed for manufacturing tablets of this type.
- Thus, for example, documents, FR-A-2 417 982 and HU-A-9960 disclose a process for manufacturing delayed-action tablets by wet granulation. More specifically, the powder mixture comprising the active principle and the various adjuvants is blended with a granulation liquid consisting of an aqueous emulsion based on a hydrophobic component such as stearic acid and nonionic hydrophilic components such as polysorbates. The resulting wet mass is then dried, after which it is passed through a screen and the granules obtained are then pelletized so as to obtain tablets. The steps of blending, screening, drying and pelletizing the powder mixture make this process long and expensive.
- Similarly, document WO 94/06416 discloses tablets consisting of a core coated with a double layer, respectively a first layer containing at least one immediate-release or modulated-release active principle, a second layer for the delayed release of active principle and an additional layer of low permeability. By means of a relatively long process, a tablet is thus obtained which has a complex structure and for which the release kinetics of the active principle are predetermined during manufacture.
- Moreover, document WO 87/04070 discloses a process for spraying onto tablets an aqueous dispersion prepared by redissolving a dried lipid emulsion, based on wax or on hydrogenated oils, in water.
- Document JP-A-53 062 821 discloses a process consisting in emulsifying a lipophilic substance melted in an aqueous phase and then in coating a pharmaceutical preparation by spraying with this emulsion at elevated temperature, above the melting point of the lipophilic substance (technique known as dry-spraying). Besides the fact that nothing is indicated regarding the nature of the coated pharmaceutical preparation, this technique has the drawback of resulting in, during spraying, an evaporation of the aqueous phase and thus in a modification of the coating conditions.
- Document WO 98/14176 discloses a process for manufacturing tablets for the sustained release of active principle which are obtained by tableting granules that are hot-coated with a lipid matrix agent. This hot-coating technique not only has the drawback of giving rise to an additional energy expenditure, but also of requiring an adaptation of the standard equipment.
- The problem which the invention proposes to solve is thus that of developing tablets for the sustained release of active principle(s) and whose manufacturing process is simple to carry out, potentially shorter and consequently less expensive than the processes proposed in the prior art.
- To do this, the invention proposes a process for manufacturing tablets for the sustained release of active principle(s), in which:
- an oil-in-water fluid emulsion is prepared;
- the emulsion obtained is sprayed onto a powder mixture comprising at least the active principle;
- the powder thus treated is subjected to a tableting step, in order to obtain tablets.
- Specifically, it has been found, entirely surprisingly, that although the coated particles have no sustained-release properties, a subsequent conventional step of tableting these particles produces tablets that have sustained-release characteristics.
- In one advantageous embodiment of the invention, the powder mixture comprises not only the active principle but also the formulation excipients.
- The expression “formulation excipient” denotes the excipients required to formulate the desired presentation form.
- Similarly, the tableting step can be carried out using any known excipient intended to promote the said tableting.
- According to a first characteristic of the invention, the spraying-air temperature is between 20° C. and 60° C., advantageously 25° C., the temperature of the emulsion being set at between 20° C. and 25° C.
- At a temperature above 60° C., the process becomes economically less viable. Moreover, a considerable risk of degradation of heat-sensitive active principles is noted.
- In other words, besides the fact that this process makes it possible to obtain sustained-release tablets, it also has the advantage of being carried out at room temperature (the temperature of the spraying air and of the emulsion is advantageously equal to 25° C.) and is thus less expensive.
- In one specific embodiment, the initial powder mixture is subjected beforehand to a granulation step in order to obtain granules.
- To facilitate the spraying of the emulsion onto the powder mixture, the said emulsion is advantageously prepared by phase inversion, so as to modify the particle size distribution, thus making it possible to reduce the particle size and hence the viscosity of the emulsion.
- According to another important characteristic of the invention, the oil-in-water fluid emulsion comprises from 5% to 35% by weight of fatty substance.
- For a concentration of less than 5%, the concentration of fatty substance is insufficient to ensure sustained release of the active principle.
- For a concentration of more than 35%, the viscosity is too high to obtain a fluid emulsion. In addition, the tableting step is difficult.
- Moreover, to allow tableting of the particles, the said particles are coated in a proportion of from 3% to 100% by weight with fluid emulsion, advantageously from 10% to 60%.
- For a coating of less than 3%, only partial coating of the particles is observed.
- Similarly, for a coating of greater than 100%, the tablet becomes too big to be a suitable presentation form.
- In order to obtain a sustained release of the active principle, the fatty substances are chosen from the group comprising fatty acids, hydrogenated oils, fatty acid esters of glycerol or of polyols, and natural waxes.
- According to a first embodiment, the fatty substance chosen is glyceryl behenate sold by the Applicant under the trade name Compritol® 888 Ato.
- According to another embodiment of the invention, the fatty substance is glyceryl palmitostearate sold by the Applicant under the trade name Precirol® Ato 5.
- To prepare the fluid emulsion at room temperature, the emulsion also contains an emulsifier or surfactant.
- The surfactant used is chosen from nonionic and/or ionic surfactants.
- More specifically, the emulsifier will be chosen so as to make the emulsion fluid and stable and to ensure the absence of formation of a foam. In addition, the emulsifier must be pharmaceutically acceptable.
- The emulsifier advantageously chosen is polyethylene glycol 4000 palmitostearate.
- According to another embodiment, the emulsifier is sodium lauryl sulfate used in a proportion of from 0.5% to 1% relative to the weight of the emulsion. Beyond 1%, no improvement of the emulsion is obtained and the formation of a foam is observed.
- Similarly, so as not to obstruct the tubes and nozzle of the spraying machine, the viscosity of the oil-in-water fluid emulsion is set at between 10 and 70 centipoises.
- The invention also relates to the tablet for the sustained release of active principle(s) which can be obtained by the process described hereinabove.
- The invention and the advantages arising therefrom will emerge more clearly from the implementation examples which follow, in support of the attached figures, in which:
- FIG. 1 is a representation of the release profile of a tablet having zero-order kinetics for dissolution of the active principle.
- FIG. 2 is a representation of the release profile of a tablet having first-order kinetics for dissolution of the active principle.
- FIG. 3 represents the release profile of theophylline granules at a spraying-air temperature of 25° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 4 represents the release profile of theophylline granules at a spraying-air temperature of 60° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 5 represents the release profile of theophylline granules at a spraying-air temperature of 25° C. for the spraying of an emulsion based on Precirol® Ato 5.
- FIG. 6 represents the release profile of theophylline granules at a spraying-air temperature of 60° C. for the spraying of an emulsion based on Precirol® Ato 5.
- FIG. 7 represents the release profile of theophylline tablets at a spraying-air temperature of 25° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 8 represents the release profile of theophylline tablets at a spraying-air temperature of 60° C. for the spraying of an emulsion based on Compritol® 888 Ato.
- FIG. 9 represents the release profile of Diclofenac tablets manufactured from an emulsion based on Compritol® 888 Ato or Precirol® Ato 5 at a spraying temperature of 25° C.
- FIG. 10 represents the release profile of the same batch of Diclofenac tablets manufactured from an emulsion based on Compritol® 888 Ato or Precirol® Ato 5 before and after stability at 40° C.
- FIG. 11 represents the release profile of Diclofenac tablets manufactured from an emulsion based on Precirol® Ato 5 at a spraying-air temperature of 25° C.
- In Examples 1 and 2 below, tablets whose active principle dissolution kinetics are said to be zero-order were manufactured according to the process of the invention.
- The expression “zero-order dissolution kinetics” denotes the constant and uniform release of the active principle as a function of time. This release may be represented graphically in the form of a curve expressed by the following equation:
- dQ/dt=k
- where Q corresponds to the amount of solution and k is the rate constant (see FIG. 1).
- Conversely, first-order kinetics correspond to a release proportional to the amount remaining in the presentation form envisaged and which decreases exponentially with time (see FIG. 2).
- In Examples 1 and 2, the in-vitro release kinetics of the active principles are determined in a dissolumeter (conventional Sotax) in accordance with the European and US pharmacopeas, at pH 1.2. The spin speed of the paddles is 100 rpm.
- This examples compares the release profile of theophylline granules coated according to the process of the invention before and after tableting with two different fatty substances, namely Compritol® 888 and Precirol® Ato 5, the spraying-air temperature being set at 25° C. or 60° C.
- 1-Preparation of the Granules
- Granules corresponding to the formula below are prepared:
theophylline monohydrate: 30 grams lactose: 41 grams wheat starch: 16 grams sodium carboxymethylcellulose: 1 gram microcrystalline cellulose: 12 grams - The granules are manufactured by wet granulation in a rotating-paddle Guedu mixer-granulator, carrying out the following steps:
- prescreening of the theophylline monohydrate
- mixing together all the constituents in the mixer for three minutes;
- blending for five minutes with 1500 ml of distilled water per five kilos of the initial mixture;
- calibration of the semi-wet granules using a screen with a mesh size of 1.25 mm;
- final oven-drying at 50° C.
- 2-Preparation of the Emulsion
- A lipid emulsion is prepared comprising:
- from 10% to 30% of fatty substance;
- 4% of stearate 4000 (surfactant);
- remainder to 100% of distilled water.
- Compritol® 888 or Precirol® Ato 5 is used as fatty substance.
- The fatty substance and the surfactant are heated until they have completely melted. The distilled water, heated to the same temperature, is added slowly with stirring. The addition of water gradually converts the initial water-in-oil emulsion into an oil-in-water emulsion. The emulsion is then homogenized with a Polytron homogenizer for three minutes in order to reduce and homogenize the size of the oil droplets.
- However, when sodium lauryl sulfate is used as surfactant, it is dissolved hot in the aqueous phase.
- 3-Spraying of the Emulsion onto the Granules Previously Obtained
- A machine with a flow of fluidized air is used, the fluidization-air temperature of which is set at 25° C. or 60° C. The fluidization pressure is set at about 1.5 bar. Similarly, the spraying rate is adjusted to 10 grams per minute.
- As already stated, the attached FIGS. 3 and 4 represent the release profile for theophylline granules coated with a lipid emulsion based on Compritol® 888 for spraying-air temperatures of 25° C. (FIG. 3) or 60° C. (FIG. 4). The proportion of Compritol® 888 ranges between 10% and 30% relative to the mass of solids used.
- As these two figures show, irrespective of the spraying-air temperature, between 80% and 90% of the active principle is dissolved within thirty minutes of ingestion. It is concluded therefrom that the granules do not have sustained-release characteristics.
- FIGS. 5 and 6 represent immediate-release profiles when the emulsion used is based on Precirol® Ato 5.
- As previously, it is found that between 80% and 95% of the active principle contained in the coated granules is released within thirty minutes.
- 4-Tableting Step
- The granules coated with Compritol® are then subjected to a step of tableting using a Frogerais OA alternating tableting machine having punches of reference size D10-R10. A mixture of talc and magnesium stearate, each representing 1% by weight relative to the total weight of the granules, is used as tableting excipient. The tablets obtained have an average weight of 402 mg and an average hardness of 5.7 kg.
- As FIGS. 7 and 8 show, the tablets obtained from the granules manufactured at a spraying temperature of 25° C. (FIG. 7) or of 60° C. (FIG. 8) show zero-order kinetics for a Compritol® concentration in the emulsion of 30%.
- Moreover, the process of the invention has the advantage of being able to be carried out at a spraying-air temperature of about only 25° C., which not only facilitates the various operations but also reduces the manufacturing cost, in particular in terms of energy consumed.
- 1-Preparation of the Granules
- Diclofenac particles are prepared under the same conditions as those of Example 1, starting with a Diclofenac/dicalcium phosphate mixture in proportions of 50/50.
- 2 and 3-Preparation of the Emulsion and Spraying
- The granules are then coated with an emulsion under the same conditions as those of Example 1, at a spraying-air temperature of 25° C., while varying the nature and concentration of the lipid substance used. A proportion of 20% or 30% of Precirol® Ato or 30% of Compritol®, relative to the mass of solids used, is thus employed.
- 4-Tableting Step
- The step of tableting the coated granules is carried out on the same tableting machine as previously. The tableting characteristics and the characteristics of the tablets obtained are collated in this table below.
Batch Batch Batch Compritol Precirol Precirol Ato 5 30% 20% 30% Coated particle: 91.4% 92% 91.4% Encompress 5.6% 6% 5.1 % Talc 2% 1% 0.5% Magnesium 0.5% 1% 1% stearate 0.5% 0% 2% Silicone talc Weight of 350 mg 300 mg 350 mg the tablet Hardness 3 kg 6 kg 3 kg Friability 0.2% 0.26% 0.30% - As shown in FIG. 9, zero-order kinetics are obtained in the three cases.
- Finally, FIG. 10 represents the release profiles of Diclofenac tablets coated with lipid emulsions comprising 20% of Compritol® 888 Ato or 20% of Precirol® Ato 5, before and after twelve months of stability at 40° C. and 75% relative humidity (accelerated stability).
- It is found that the active principle remains stable and that a very satisfactory stability of the dissolution kinetics for the Diclofenac tablets is conserved.
- In contrast with Example 2, no prior wet granulation of the active principle is carried out in this example.
- 1-Preparation of the Fluid Emulsion
- A fluid emulsion is prepared containing 10% of identical fatty substance under the same conditions as those used in Examples 1 and 2.
- 2-Spraying
- The powder mixture consisting of a mixture of Diclofenac/dicalcium phosphate in proportions of 50/50 is then coated so as to obtain coated particles with good tableting properties.
- The emulsion is sprayed onto the particles under the same conditions as those of Example 1, at a spraying-air temperature of about 25° C.
- 3-Tableting Step
- The step of tableting the coated particles is carried out on an industrial rotary tableting machine. The tableting characteristics and the characteristics of the tablets obtained are as follows:
Coated particle 92% Encompress 6 % Talc 1 % Magnesium stearate 1% Average weight of the tablet 280 mg Hardness 33 Newtons - FIG. 11 represents the release profile of Diclofenac tablets in which the proportion of Precirol® Ato 5 relative to the mass of solids used is 20%.
- The in-vitro release kinetics of the Diclofenac are evaluated in a dissolumeter in accordance with the European, US and Japanese pharmacopeas, at pH 6.8, according to the provisions of US pharmacopea, edition XXIII. The spin speed of the paddles is 50 rpm.
- As shown in FIG. 11, the two tests carried out on the same batch show a profile of sustained release of the active principle over 12 hours.
- The advantages of the invention emerge clearly from the description.
- It will be noted in particular that the process of the invention makes it possible to obtain tablets with sustained release over 12 hours, allowing the doses to be adapted to two intakes a day.
- The ease of implementation of the process, consisting in spraying a lipid emulsion at temperatures ranging between 20° C. and 60° C., also contributing toward reducing the energy cost of the operations, will moreover be noted.
- Finally, it is found that the tablets obtained have very satisfactory long-term stability.
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR98.07725 | 1998-06-16 | ||
FR9807725A FR2779651B1 (en) | 1998-06-16 | 1998-06-16 | PROCESS FOR THE MANUFACTURE OF SUSTAINED RELEASE TABLETS OF ACTIVE INGREDIENT (S) HAVING ZERO-SIZE DISSOLUTION KINETICS |
PCT/FR1999/001443 WO1999065471A1 (en) | 1998-06-16 | 1999-06-16 | Method for making tablets with active principle sustained-release |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001443 Continuation WO1999065471A1 (en) | 1998-06-16 | 1999-06-16 | Method for making tablets with active principle sustained-release |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010003590A1 true US20010003590A1 (en) | 2001-06-14 |
US6379700B2 US6379700B2 (en) | 2002-04-30 |
Family
ID=9527571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/733,668 Expired - Fee Related US6379700B2 (en) | 1998-06-16 | 2000-12-08 | Process for manufacturing tablets for the sustained release of active principle(s) |
Country Status (5)
Country | Link |
---|---|
US (1) | US6379700B2 (en) |
EP (1) | EP1087757A1 (en) |
JP (1) | JP2002518320A (en) |
FR (1) | FR2779651B1 (en) |
WO (1) | WO1999065471A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050123627A1 (en) * | 2003-12-04 | 2005-06-09 | Pfizer Inc | Azithromycin dosage forms with reduced side effects |
US20050123616A1 (en) * | 2003-12-04 | 2005-06-09 | Pfizer Inc | Azithromycin multiparticulate dosage forms by liquid-based processes |
US20050181060A1 (en) * | 2003-12-04 | 2005-08-18 | Pfizer Inc | Method of making pharmaceutical multiparticulates |
US20050181061A1 (en) * | 2003-12-04 | 2005-08-18 | Pfizer Inc | Extrusion process for forming chemically stable drug multiparticulates |
US7736672B2 (en) | 2003-12-04 | 2010-06-15 | Pfizer, Inc. | Multiparticulate compositions with improved stability |
US7887844B2 (en) | 2003-12-04 | 2011-02-15 | Pfizer Inc. | Multiparticulate crystalline drug compositions having controlled release profiles |
KR102380498B1 (en) * | 2021-02-24 | 2022-04-01 | 주식회사 청안오가닉스 | Composition for manufacturing sustained-release tablets capable of controlling sustained release of active ingredients in health functional food |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150374826A1 (en) * | 1999-06-30 | 2015-12-31 | Lipocine Inc. | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6692771B2 (en) | 2001-02-23 | 2004-02-17 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
US7052706B2 (en) | 2001-06-08 | 2006-05-30 | Nostrum Pharmaceuticals, Inc. | Control release formulation containing a hydrophobic material as the sustained release agent |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100392A1 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
WO2002100344A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
ITMI20012366A1 (en) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | THERAPEUTIC SYSTEMS STABILIZED WITH IMMEDIATE RELEASE AND / OR MODIFIED FOR THE ORAL ADMINISTRATION OF ACTIVE AND / OR EXCIPIENT PRINCIPLES AND / OR WINGS |
WO2004052841A1 (en) | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
US20040146553A1 (en) * | 2002-12-23 | 2004-07-29 | Aventis Pharma S.A. | Compositions for oral administration of active principles requiring masking of taste |
DE10300325A1 (en) | 2003-01-09 | 2004-07-22 | Hexal Ag | Granules with oily substance, manufacturing process and tablet |
US20040254246A1 (en) * | 2003-03-31 | 2004-12-16 | Barrett Ronald W. | Treating or preventing hot flashes using prodrugs of GABA analogs |
WO2005019163A2 (en) * | 2003-08-20 | 2005-03-03 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
EP2354120A1 (en) | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
US7700652B2 (en) * | 2003-09-11 | 2010-04-20 | Xenoport, Inc. | Treating urinary incontinence using prodrugs of GABA analogs |
KR101157436B1 (en) * | 2003-09-17 | 2012-07-05 | 제노포트 인코포레이티드 | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
FR2861990B1 (en) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | LOW DOSAGE TABLETS WITH POLYMER NETWORK |
US20060128676A1 (en) * | 2004-07-13 | 2006-06-15 | Pharmacofore, Inc. | Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain |
WO2006050472A2 (en) * | 2004-11-03 | 2006-05-11 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids |
US7566738B2 (en) * | 2004-11-03 | 2009-07-28 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
NZ554737A (en) * | 2004-11-04 | 2011-04-29 | Xenoport Inc | Gabapentin prodrug sustained release oral dosage forms |
DE602006014694D1 (en) | 2005-06-20 | 2010-07-15 | Xenoport Inc | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAN ACID AND APPLICATION |
WO2007027476A2 (en) * | 2005-08-26 | 2007-03-08 | Xenoport, Inc. | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
EP2046393B1 (en) | 2006-05-26 | 2014-02-12 | Signature Therapeutics, Inc. | Controlled release of phenolic opioids |
WO2008033572A1 (en) * | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
JP2010512314A (en) * | 2006-12-08 | 2010-04-22 | ゼノポート,インコーポレーテッド | Use of GABA analog prodrugs to treat disease |
US20090060993A1 (en) * | 2007-09-04 | 2009-03-05 | Joseph Schwarz | Solid pharmaceutical composition for enhanced delivery of coenzyme q-10 and ubiquinones |
WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
WO2012050907A2 (en) | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
CA2998708C (en) | 2015-10-01 | 2019-09-03 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
CA3056239C (en) | 2017-03-17 | 2023-09-12 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
EP3793974A4 (en) | 2018-05-14 | 2022-05-04 | Xgene Pharmaceutical Inc | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU179474B (en) | 1978-02-24 | 1982-10-28 | Laszlo Gyarmati | Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material |
DE3346525A1 (en) * | 1983-12-22 | 1985-07-04 | A. Nattermann & Cie GmbH, 5000 Köln | PHARMACEUTICAL PREPARATION WITH SPECIAL 1,2-DIACYL-GLYCERO-3-PHOSPHOCHOLINES FOR THE TREATMENT OF DISEASES IN THE GASTIC COLON |
WO1987004070A1 (en) * | 1986-01-13 | 1987-07-16 | Research Corporation | Aqueous dispersions of waxes and lipids for pharmaceutical coating |
IT1255522B (en) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS |
GB9224855D0 (en) * | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
JPH08198776A (en) * | 1995-01-23 | 1996-08-06 | Shin Etsu Chem Co Ltd | Production of emulsion for drug coating |
FR2753904B1 (en) * | 1996-10-01 | 1998-10-30 | Gattefosse Ets Sa | PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE SUBSTANCE, INCLUDING A MATRIX, AND MANUFACTURING PROCESS |
-
1998
- 1998-06-16 FR FR9807725A patent/FR2779651B1/en not_active Expired - Fee Related
-
1999
- 1999-06-16 JP JP2000554351A patent/JP2002518320A/en not_active Withdrawn
- 1999-06-16 WO PCT/FR1999/001443 patent/WO1999065471A1/en not_active Application Discontinuation
- 1999-06-16 EP EP99925111A patent/EP1087757A1/en not_active Withdrawn
-
2000
- 2000-12-08 US US09/733,668 patent/US6379700B2/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050123627A1 (en) * | 2003-12-04 | 2005-06-09 | Pfizer Inc | Azithromycin dosage forms with reduced side effects |
US20050123616A1 (en) * | 2003-12-04 | 2005-06-09 | Pfizer Inc | Azithromycin multiparticulate dosage forms by liquid-based processes |
US20050181060A1 (en) * | 2003-12-04 | 2005-08-18 | Pfizer Inc | Method of making pharmaceutical multiparticulates |
US20050181061A1 (en) * | 2003-12-04 | 2005-08-18 | Pfizer Inc | Extrusion process for forming chemically stable drug multiparticulates |
US20060029677A1 (en) * | 2003-12-04 | 2006-02-09 | Pfizer Inc | Azithromycin dosage forms with reduced side effects |
US7736672B2 (en) | 2003-12-04 | 2010-06-15 | Pfizer, Inc. | Multiparticulate compositions with improved stability |
US7887844B2 (en) | 2003-12-04 | 2011-02-15 | Pfizer Inc. | Multiparticulate crystalline drug compositions having controlled release profiles |
US7951403B2 (en) | 2003-12-04 | 2011-05-31 | Pfizer Inc. | Method of making pharmaceutical multiparticulates |
KR102380498B1 (en) * | 2021-02-24 | 2022-04-01 | 주식회사 청안오가닉스 | Composition for manufacturing sustained-release tablets capable of controlling sustained release of active ingredients in health functional food |
Also Published As
Publication number | Publication date |
---|---|
FR2779651A1 (en) | 1999-12-17 |
JP2002518320A (en) | 2002-06-25 |
FR2779651B1 (en) | 2001-04-20 |
EP1087757A1 (en) | 2001-04-04 |
US6379700B2 (en) | 2002-04-30 |
WO1999065471A1 (en) | 1999-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6379700B2 (en) | Process for manufacturing tablets for the sustained release of active principle(s) | |
DE69917937T2 (en) | CONTROLLED RELEASE FORMULATIONS THAT HAVE A FAST ADMISSION AND FAST WASTE OF EFFECTIVE DRUG PLASMA CONCENTRATIONS | |
DE60121857T2 (en) | Drug composition with delayed release of active ingredient | |
US5126145A (en) | Controlled release tablet containing water soluble medicament | |
RU2245136C2 (en) | Composition containing fine dispersed long releasing particles for quick-disposable in buccal cavern tablets | |
DE69434479T2 (en) | Tramadol-containing drug with controlled release of active ingredient | |
US6020003A (en) | Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin | |
US6194005B1 (en) | Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix | |
EP1809260B1 (en) | Aqueous pharmaceutical coating | |
EP1025848A1 (en) | Sustained-release theophylline tablet | |
JP2003508428A (en) | Oral pharmaceutical dosage form for sustained release | |
NO314566B1 (en) | Controlled release dosage form coated with aqueous dispersions of ethyl cellulose, as well as method and application | |
WO2010080580A2 (en) | Extended-release pharmaceutical formulations | |
US20100160363A1 (en) | Extended-release pharmaceutical formulations | |
JPS6056122B2 (en) | sustained release formulation | |
EP0388954A2 (en) | Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions | |
EP0368216A1 (en) | Solid pharmaceutical retard form | |
DE69937891T2 (en) | FLUVASTATIN MEDICINAL PRODUCT WITH DELAYED ACTIVE INGREDIENTS | |
EP1020186B1 (en) | Process for the manufacture of a sustained release tramadol preparation with a storage stable release profile without curing of the coated product | |
AU748396B2 (en) | Composition | |
EP1267828A2 (en) | Pharmaceutical preparations | |
DE202019005769U1 (en) | Pediatric dosage forms of vitamin D and uses | |
WO2004058226A1 (en) | Methods for coating substrates for pharmaceutical uses with a mixture of two film-forming coating agents | |
IL192091A (en) | Sustained release pharmaceutical compositions comprising liothyronine, process for their preparation and their use in the manufacture of medicaments | |
US5726201A (en) | Gemfibrozil containing pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GATTEFOSSE S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOACHIM, JOSEPH;PRINDIRRE, PASCAL;FARAH, NABIL;REEL/FRAME:011364/0269 Effective date: 20001110 Owner name: LABORATOIRES PROGRAPHARM, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOACHIM, JOSEPH;PRINDIRRE, PASCAL;FARAH, NABIL;REEL/FRAME:011364/0269 Effective date: 20001110 |
|
AS | Assignment |
Owner name: ETHYPHARM, FRANCE Free format text: ASSIGNMENT - 50% INTEREST;ASSIGNOR:LABORATOIRES PROGRAPHARM;REEL/FRAME:012209/0021 Effective date: 20010816 |
|
REMI | Maintenance fee reminder mailed | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20060430 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140430 |